KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Long-Term Investments (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Long-Term Investments for 17 consecutive years, with $492.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments fell 5.56% year-over-year to $492.2 million, compared with a TTM value of $492.2 million through Dec 2025, down 5.56%, and an annual FY2025 reading of $492.2 million, down 5.56% over the prior year.
  • Long-Term Investments was $492.2 million for Q4 2025 at Biomarin Pharmaceutical, down from $512.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $620.6 million in Q1 2024 and bottomed at $321.1 million in Q1 2021.
  • Average Long-Term Investments over 5 years is $469.7 million, with a median of $499.5 million recorded in 2025.
  • The sharpest move saw Long-Term Investments tumbled 34.26% in 2022, then surged 83.06% in 2023.
  • Year by year, Long-Term Investments stood at $507.8 million in 2021, then crashed by 34.26% to $333.8 million in 2022, then soared by 83.06% to $611.1 million in 2023, then fell by 14.71% to $521.2 million in 2024, then decreased by 5.56% to $492.2 million in 2025.
  • Business Quant data shows Long-Term Investments for BMRN at $492.2 million in Q4 2025, $512.9 million in Q3 2025, and $508.6 million in Q2 2025.